ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 34
| Issue : 1 | Page : 305-309 |
|
Genetic polymorphism of BCL11A (rs11886868) in Egyptian patients with β-thalassemia
Mohamed A Soliman1, Rawhia H El-Edel1, Amal H AbdElhameed2, Seham M Ragab3, Manal Monir Mansour1, Mohamed A Helwa1
1 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt 2 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt 3 Department of Pediatrics, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Correspondence Address:
Manal Monir Mansour Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_232_19
|
|
Objectives
To study the effect of BCL11A (rs11886868) gene polymorphism on clinical status of Egyptian patients with β-thalassemia.
Background
β-thalassemia is a genetic disorder that results from β-globin gene mutations leading to defective synthesis of adult hemoglobin (Hb A). Clinical consequences vary tremendously from nearly asymptomatic to severely anemic and transfusion-dependent patients. Phenotypic variations have been linked not only to the type of β-globin gene mutations and amount of synthesized Hb A but also to recently discovered genetic modifiers mapping outside the β-globin gene cluster including BCL11A gene polymorphism. These modifiers are associated with increased fetal hemoglobin (Hb F) levels.
Patients and methods
Blood samples were collected from 120 patients with β-thalassemia before transfusion of blood. Complete blood count, quantitative measurement of different Hb types by high-performance liquid chromatography, and analysis of single nucleotide polymorphism rs11886868 in the BCL11A gene by Taqman single nucleotide polymorphism genotyping assay and real-time PCR were done.
Results
The genotype distribution of BCL11A gene polymorphism showed low frequency of CC genotype (15%) among Egyptian patients with β-thalassemia. The CT genotype was 41.7% and TT genotype was 43.3%. There was a significant relation between BCL11A (rs11886868) genotypes and Hb F levels, with the highest Hb F levels were observed in the CC genotype followed by CT genotype, whereas Hb F levels were the lowest in TT genotype. Patients with CC genotype had mild disease phenotype owing to increased Hb F production. Hb F utilizes some of the free α-chain and ameliorates clinical presentation.
Conclusion
Screening of BCL11A gene variants may be used as a marker for severity risk in newly diagnosed patients with β-thalassemia and as a predictor of clinical outcome of this disorder.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|